Vimarsana
Biggest News Aggregation in the World

Page 35 - Cll News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cll. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cll Today - Breaking & Trending Today

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More - Vimarsana News

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.

Real-World Study Confirms Efficacy of Venetoclax Alone, After BTKi Therapy in CLL - Vimarsana News

Real-World Study Confirms Efficacy of Venetoclax Alone, After BTKi Therapy in CLL

Researchers found that venetoclax, either alone or post treatment with a Bruton tyrosine kinase inhibitor (BTKi), was safe and effective for patients with chronic lymphocytic leukemia (CLL).

Source: ajmc.com
ASH Abstracts Showcase Effective Treatments for MM, CLL, FL - Vimarsana News

ASH Abstracts Showcase Effective Treatments for MM, CLL, FL

Abstracts from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition provided new insight into multiple treatments for patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL).

Source: ajmc.com
Exploring the Role of BTKi-Based Combination Therapies for Front-line Management of CLL - Vimarsana News

Exploring the Role of BTKi-Based Combination Therapies for Front-line Management of CLL

Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).

Treatment Sequencing Strategies for R/R CLL: Impact of Prior 1L Therapy - Vimarsana News

Treatment Sequencing Strategies for R/R CLL: Impact of Prior 1L Therapy

Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.